Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Charles River Laboratories Intl. Inc (CRL) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance

Charles River Laboratories Intl. IncTrade
Virgin Galactic Holdings, Inc.Trade

Price performance (Past 24H)

Key statistics

Charles River Laboratories Intl. Inc vs Virgin Galactic Holdings, Inc. — how do they compare? Charles River Laboratories Intl. Inc trades at $287.73 (market cap $13.46B), while Virgin Galactic Holdings, Inc. trades at $3.31 (market cap $498.02M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 27× Virgin Galactic Holdings, Inc.'s market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals.

CRLSPCE
Market Cap
$13.46B$498.02M
Sector
HealthIndustrials
52-Week High
$282.00$7.52
52-Week Low
$145.57$2.17
Enterprise Value
$16.30B$597.87M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Charles River Laboratories Intl. Inc

Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.

While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.

Virgin Galactic Holdings, Inc.

Virgin Galactic (SPCE) trades at $3.26, up 0.77% today, with technical indicators showing bullish momentum despite overbought RSI readings. The company continues to face significant fundamental challenges with negative profit margins (-19,781.3% net income margin) and declining revenue, though recent earnings have consistently beaten expectations. Cash flow remains negative but shows improvement trend from -$207M in 2022 to -$35M in 2025.

While technical momentum appears positive, SPCE's fundamental weakness and high cash burn present substantial risks. The stock offers speculative appeal for investors betting on space tourism commercialization, but requires careful risk management given persistent losses and competitive pressures in the emerging space sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Charles River Laboratories Intl. Inc

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.

Read more on CRL

About Virgin Galactic Holdings, Inc.

Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.

Read more on SPCE